Comtan (entacapone), a new drug for advanced Parkinson's disease
Novartis is now introducing Comtan (entacapone), a new drug for advanced Parkinson's disease.
It's given to enhance the effectiveness of levodopa/carbidopa (Sinemet, etc).
Comtan is a COMT inhibitor...in the same class as Tasmar (tolcapone). But Comtan isn't expected to have the same problems with liver toxicity.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote